Spectrofluorometric Analysis of New-Generation Antidepressant Drugs in Pharmaceutical Formulations, Human Urine, and Plasma Samples

Table 5

Evaluation of accuracy and precision of the proposed method in urine.

Amount added (ng/μL)IntradayInterday
FoundRecoveryFoundRecovery
(ng/μL) ± SD1± RSD3 (%)(ng/μL) ± SD1± RSD3 (%)

SER
 10 0 8 . 8 0 ± 0 . 0 7 7 8 8 . 0 ± 2 . 0 8 0 8 . 9 7 ± 0 . 1 6 3 8 9 . 7 0 ± 2 . 1 7
 50 4 9 . 3 4 ± 0 . 0 9 6 9 8 . 6 9 ± 3 . 1 9 4 8 . 4 5 ± 0 . 0 2 6 9 6 . 9 0 ± 3 . 6 8
 100 9 8 . 0 5 ± 0 . 0 4 4 9 8 . 0 5 ± 4 . 2 2 9 8 . 2 5 ± 0 . 0 1 6 9 8 . 2 5 ± 4 . 2 6

PAR
 10 0 8 . 4 0 ± 0 . 0 9 6 8 4 . 0 ± 1 . 2 5 0 8 . 7 0 ± 0 . 1 1 5 8 7 . 0 ± 2 . 9 0
 50 4 8 . 3 5 ± 0 . 0 9 2 9 6 . 7 0 ± 4 . 4 9 4 7 . 6 6 ± 0 . 0 1 9 9 5 . 3 2 ± 5 . 7 1
 100 9 8 . 1 1 ± 0 . 0 6 8 9 8 . 1 1 ± 5 . 0 6 9 8 . 1 9 ± 0 . 1 2 0 9 8 . 1 9 ± 5 . 1 1

CIT
 10 0 9 . 0 9 ± 0 . 0 5 9 9 0 . 9 0 ± 2 . 0 7 0 8 . 2 9 ± 0 . 0 9 3 8 2 . 9 0 ± 1 . 7 0
 50 4 8 . 9 2 ± 0 . 0 6 8 9 7 . 8 4 ± 3 . 1 9 4 8 . 1 5 ± 0 . 1 1 2 9 6 . 3 0 ± 4 . 7 0
 100 9 7 . 6 2 ± 0 . 6 6 3 9 7 . 6 2 ± 5 . 1 6 9 6 . 5 1 ± 0 . 0 5 4 9 6 . 5 1 ± 6 . 8 9

VLF
 10 0 8 . 7 0 ± 0 . 0 8 4 8 7 . 0 ± 2 . 9 4 0 8 . 7 0 ± 0 . 0 9 3 8 7 . 0 ± 1 . 8 3
 50 4 8 . 0 7 ± 0 . 1 1 3 9 6 . 3 4 ± 4 . 1 5 4 7 . 2 2 ± 0 . 1 5 6 9 4 . 4 4 ± 5 . 4 8
 100 9 7 . 0 3 ± 0 . 0 7 9 9 7 . 0 3 ± 4 . 2 7 9 6 . 2 1 ± 0 . 1 0 2 9 6 . 2 1 ± 4 . 9 5

FLX
 10 0 8 . 4 6 ± 0 . 1 0 5 8 4 . 6 0 ± 1 . 4 3 0 9 . 5 8 ± 0 . 1 6 1 9 5 . 8 0 ± 2 . 2 5
 50 4 7 . 9 8 ± 0 . 1 0 8 9 5 . 9 6 ± 3 . 0 2 4 8 . 1 1 ± 0 . 0 7 6 9 6 . 2 2 ± 4 . 1 3
 100 9 8 . 1 7 ± 0 . 1 1 0 9 8 . 1 7 ± 4 . 1 1 9 7 . 4 0 ± 0 . 2 2 8 9 7 . 4 0 ± 5 . 6 7

1 A verage of six replicate determinations and their standard deviation (SD); 2RSD: relative standard deviation.